Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment ...

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin ...

The FDA has approved topical difamilast for treating mild-to-moderate atopic dermatitis (AD) in adults and children aged 2 years or older, according to a press release from the manufacturer, Acrotech ...

The phase 2b REZOLVE-AD trial enrolled 393 adults with moderate-to-severe atopic dermatitis across approximately 110 global ...

Tralokinumab is effective for the treatment of AD through 72 weeks across body regions, including the head/neck, trunk, and limbs.

ZORYVE ® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, ...

The start of 2026 has been a period of strong execution and momentum across our clinical programs, broadly, and with ATI-052 specifically,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “The ...

Researchers have found in a new study that there is no general association between atopic dermatitis (AD) and contact ...

The atopic dermatitis market offers opportunities in developing new and innovative therapies, with over 100 companies and 110 drugs in various stages of development. Key areas include novel biologic ...

Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve ...

From reducing lesions to truly improving quality of life. Today, the management of psoriasis and atopic dermatitis is ...

Montana’s harsh climate, with low humidity and extreme temperatures, commonly exacerbates dry skin, especially in the wintertime. In susceptible individuals, dry skin may manifest as eczema flares, ...